Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NC-503 · 2 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| A | PLACEBO_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NC-503 (eprodisate disodium) | DRUG | capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks |
| placebo | OTHER | Dosage: 4 capsules BID for 26 weeks |
| NC-503 (Anti-amyloidotic (AA) Agent) | DRUG | - |
Inclusion Criteria: * Age and gender eligibility: 30 years and older * Diagnosis of Type 2 diabetes mellitus * Patients treated with a stable therapeutic dose of either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent for a minimum period of 3 months prior to t...
NC-503 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is also being studied in patients with Metabolic Syndrome X. The drug is currently in Phase 2 clinical development and is not approved by regulatory authorities.
NC-503 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Type 2 Diabetes Mellitus.
NC-503 is in Phase 2 clinical development. A Phase IIa proof-of-concept study has been completed, which enrolled 200 participants with Type 2 Diabetes Mellitus. The drug is still investigational and has not received regulatory approval for any indication.
NC-503 has one completed clinical trial registered under NCT00675857, titled "A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes." This was a randomized, double-blind, placebo-controlled study conducted in Canada with 200 participants aged 30 years and older.
NC-503 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Type 2 Diabetes Mellitus. The completed Phase IIa study was a proof-of-concept trial, and the drug has not yet progressed to later-stage trials or regulatory submission.